Drug intelligence / Profile preview

2LXFS

Development stage: Phase 4
Lead developer: Labo'Life
Modality: DNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes
Administration: Oral

Overview

2LXFS is a micro-immunotherapy drug developed by Labo'Life, designed to treat chronic viral infections, particularly those caused by the Epstein-Barr virus (EBV) and cytomegalovirus (CMV). It utilizes a combination of low-dose immunocompetent substances, including deoxyribonucleic acid (DNA), interleukin-1, interleukin-2, and interferon alfa, to modulate the host's immune response and inhibit viral replication. The treatment is administered orally via capsules in a specific sequential order (1 through 10) to mimic the natural physiological immune response. It is primarily evaluated for its efficacy in reducing asthenia (fatigue) and other symptoms associated with EBV infection.

Brand names: 2LXFS
Other names: 2LXFS

Targets

IFNAR (Immune system modulation via type I interferon receptor)IL-2R (Interleukin-2/interleukin-15 receptor complex)IL-1R (Interleukin-1 receptor type 1 (IL-1R1))DNA

Beyond the preview

Go deeper on 2LXFS.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 2LXFS.

Explore the full profile